Page last updated: 2024-08-16

rivastigmine and Hyperhomocysteinemia

rivastigmine has been researched along with Hyperhomocysteinemia in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Coutinho-Silva, R; Dos Santos, TM; Leite-Aguiar, R; Ramires Junior, OV; Savio, LEB; Silveira, JS; Wyse, ATS1
Barone, P; Burn, DJ; Hsu, C; Lane, RM; Poewe, W; van Laar, T1
Ballard, C; Emre, M; He, Y; Lane, R; Leverenz, JB; Morris, C1

Trials

1 trial(s) available for rivastigmine and Hyperhomocysteinemia

ArticleYear
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Aug-15, Volume: 23, Issue:11

    Topics: Aged; Analysis of Variance; Dementia; Double-Blind Method; Female; Homocysteine; Humans; Hyperhomocysteinemia; Male; Mental Status Schedule; Middle Aged; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index

2008

Other Studies

2 other study(ies) available for rivastigmine and Hyperhomocysteinemia

ArticleYear
Rivastigmine Reverses the Decrease in Synapsin and Memory Caused by Homocysteine: Is There Relation to Inflammation?
    Molecular neurobiology, 2022, Volume: 59, Issue:7

    Topics: Acetylcholinesterase; Animals; Homocysteine; Hyperhomocysteinemia; Ibuprofen; Inflammation; Male; Oxidative Stress; Rats; Rats, Wistar; Rivastigmine; Synapsins

2022
BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Feb-15, Volume: 24, Issue:3

    Topics: Aged; Apolipoprotein E4; Butyrylcholinesterase; Cognition Disorders; Female; Gene Frequency; Genotype; Humans; Hyperhomocysteinemia; Lewy Body Disease; Male; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Psychomotor Disorders; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index

2009